Stock NGNE NEUROGENE INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Neurogene Inc.

Equities

NGNE

US64135M1053

Real-time Estimate Cboe BZX
Other stock markets
 11:58:17 2024-04-29 am EDT 		5-day change 1st Jan Change
31.75 USD +5.97% Intraday chart for Neurogene Inc. +5.03% +65.89%
01:30pm Leerink Partners Starts Neurogene With Outperform Rating, $46 Price Target MT
Mar. 22 North American Morning Briefing : Stocks Struggle After New Records DJ

Evolution of the average Target Price on Neurogene Inc.

Price target over the last 5 years

History of analyst recommendation changes

6677a41caade6bfaa2356.VBIzEIS5HWaresUuUZfxDuQ1HKEKM_LTOtgAJIj59hQ.M1NCVamJUlPNC69YCa-3XqdjeP58e63md4dLXcO6sFdhW0R268MqPN4QgA~e3248ae36ca43679034f22594eb9c3a1

Analyst Recommendations on Neurogene Inc.

Leerink Partners Starts Neurogene With Outperform Rating, $46 Price Target MT
William Blair Initiates Neurogene With Outperform Rating MT
HC Wainwright Starts Neurogene With Buy Rating, $45 Price Target MT
Stifel Starts Coverage on Neurogene with Buy Rating, $31 Price Target MT
Mizuho Adjusts Price Target on Neoleukin Therapeutics to $1.50 From $2, Keeps Neutral Rating MT
North American Morning Briefing : Stock Futures Dip as Higher Rate Fears Persist DJ
Guggenheim Downgrades Neoleukin Therapeutics to Neutral From Buy MT
Mizuho Downgrades Neoleukin Therapeutics to Neutral From Buy, Adjusts Price Target to $2 From $21 MT
Canaccord Genuity Downgrades Neoleukin Therapeutics to Hold From Buy, Adjusts Price Target to $1 From $10 MT
BofA Securities Downgrades Neoleukin Therapeutics to Underperform From Buy, Adjusts Price Target to $1 From $3 MT
HC Wainwright Adjusts Neoleukin Therapeutics' Price Target to $6 from $22, Maintains Buy Rating MT
Stifel Nicolaus Adjusts Price Target for Neoleukin Therapeutics to $14 From $18, Maintains Buy Rating MT
Canaccord Genuity Assumes Neoleukin Therapeutics at Buy with $10 Price Target MT
Piper Sandler Adjusts Price Target on Neoleukin Therapeutics to $6 From $25, Reiterates Overweight Rating MT
Guggenheim Adjusts Price Target for Neoleukin Therapeutics to $12 From $16, Maintains Buy Rating MT
Piper Sandler Adjusts Neoleukin Therapeutics Price Target to $25 From $30, Maintains Overweight Rating MT
NEOLEUKIN THERAPEUTICS : Piper Sandler Starts Neoleukin Therapeutics at Overweight with $30 Price Target MT
NEOLEUKIN THERAPEUTICS : Stifel Starts Neoleukin Therapeutics at Buy With $18 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
29.96 USD
Average target price
53.33 USD
Spread / Average Target
+78.02%
High Price Target
61 USD
Spread / Highest target
+103.60%
Low Price Target
44 USD
Spread / Lowest Target
+46.86%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Neurogene Inc.

Leerink Partners
William Blair & Co.
HC Wainwright
Stifel Nicolaus
Mizuho Securities
Guggenheim
Canaccord Genuity
BofA Securities
Piper Sandler

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. NGNE Stock
  4. Consensus Neurogene Inc.